BREAKING: Largest Real-World Analysis of Ivermectin + Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit — Nearly HALF Report Cancer Disappearance or Regression
After just 6 months, 48.4% of cancer patients taking ivermectin and mebendazole reported no evidence of disease (32.8%) or tumor regression (15.6%), while 36.1% reported disease stabilization.
APR 07, 2026
At approximately six months, outcomes were distributed as follows:
No Evidence of Disease (NED): 32.8% (95% CI: 25.1–41.5%)
Tumor Regression: 15.6% (95% CI: 10.2–23.0%)
Stable Disease: 36.1% (95% CI: 28.1–44.9%)
Progression: 15.6% (95% CI: 10.2–23.0%)
This yields a Clinical Benefit Ratio (CBR) of 84.4% (95% CI: 77.0–89.8%), meaning more than four out of five patients reported either improvement or stabilization of their cancer.
Critically, the 48.4% rate of NED + regression (95% CI: 39.7–57.1%) represents the strongest signal—indicating that a substantial proportion of patients did not merely stabilize, but reported meaningful reversal of disease burden.
CONCLUSION
This first-ever real-world analysis of a ivermectin–mebendazole protocol in human cancer patients provides a compelling signal that demands serious attention. While these findings should be interpreted appropriately as hypothesis-generating evidence from a real-world clinical evaluation, the magnitude, internal consistency, and broad distribution of the observed effects cannot be ignored. We are not observing marginal changes or isolated responses—we are observing widespread self-reported disease control across a diverse cancer population, a substantial proportion of patients reporting complete disappearance of detectable cancer, and sustained adherence with favorable tolerability over time.
****************************
***************************************
No comments:
Post a Comment